Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Toni K. Choueiri, M.D.

Co-Author

This page shows the publications co-authored by Toni Choueiri and Ziad El Bakouny.
Connection Strength

7.107
  1. Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1042-1044.
    View in: PubMed
    Score: 0.490
  2. Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncol. 2021 May 01; 7(5):773-775.
    View in: PubMed
    Score: 0.485
  3. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243.
    View in: PubMed
    Score: 0.479
  4. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021 04; 18(4):199-214.
    View in: PubMed
    Score: 0.475
  5. Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. Cancer J. 2020 Sep/Oct; 26(5):464-470.
    View in: PubMed
    Score: 0.463
  6. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. JCO Glob Oncol. 2020 08; 6:1248-1257.
    View in: PubMed
    Score: 0.460
  7. IL-8 and cancer prognosis on immunotherapy. Nat Med. 2020 05; 26(5):650-651.
    View in: PubMed
    Score: 0.452
  8. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
    View in: PubMed
    Score: 0.452
  9. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.438
  10. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Focus. 2020 01 15; 6(1):37-40.
    View in: PubMed
    Score: 0.417
  11. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.239
  12. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol. 2020 10 01; 6(10):1606-1610.
    View in: PubMed
    Score: 0.233
  13. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020 08; 135:203-210.
    View in: PubMed
    Score: 0.229
  14. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.227
  15. Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021 Aug 27; 166:103463.
    View in: PubMed
    Score: 0.124
  16. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):649-661.e5.
    View in: PubMed
    Score: 0.120
  17. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.120
  18. Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncol. 2021 03 01; 7(3):458-460.
    View in: PubMed
    Score: 0.120
  19. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.119
  20. COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell. 2020 11 09; 38(5):629-646.
    View in: PubMed
    Score: 0.116
  21. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
    View in: PubMed
    Score: 0.114
  22. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020 02; 8(1).
    View in: PubMed
    Score: 0.111
  23. The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. Eur J Cancer. 2020 03; 127:118-122.
    View in: PubMed
    Score: 0.111
  24. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019 12; 76(6):861-867.
    View in: PubMed
    Score: 0.108
  25. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021 10; 160:78-83.
    View in: PubMed
    Score: 0.061
  26. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 06; 32(6):787-800.
    View in: PubMed
    Score: 0.060
  27. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. Cancer Cell. 2020 Dec 14; 38(6):769-770.
    View in: PubMed
    Score: 0.059
  28. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020 10; 10(10):1514-1527.
    View in: PubMed
    Score: 0.057
  29. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918.
    View in: PubMed
    Score: 0.057
  30. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. 2020 10; 78(4):615-623.
    View in: PubMed
    Score: 0.057
  31. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 10 15; 25(20):6080-6088.
    View in: PubMed
    Score: 0.054
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.